Barclays Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) had its price objective lifted by stock analysts at Barclays from $10.00 to $11.00 in a research report issued on Monday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's target price would indicate a potential upside of 25.57% from the stock's previous close.

A number of other equities research analysts also recently commented on the stock. StockNews.com downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, Piper Sandler increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $10.80.

Remove Ads

Amneal Pharmaceuticals Trading Down 2.3 %

AMRX traded down $0.21 during trading hours on Monday, hitting $8.76. 2,450,835 shares of the company's stock were exchanged, compared to its average volume of 1,410,147. The firm has a 50 day moving average of $8.16 and a 200 day moving average of $8.34. Amneal Pharmaceuticals has a 12-month low of $5.18 and a 12-month high of $9.48. The firm has a market cap of $2.71 billion, a P/E ratio of -12.88 and a beta of 1.10.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The company had revenue of $730.52 million during the quarter, compared to analysts' expectations of $708.21 million. During the same period last year, the firm earned $0.14 earnings per share. As a group, research analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 17,410 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the transaction, the director now directly owns 2,031,476 shares of the company's stock, valued at $16,272,122.76. The trade was a 0.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 240,000 shares of company stock worth $2,004,000 in the last 90 days. 26.56% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AMRX. Gladius Capital Management LP acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $37,000. GF Fund Management CO. LTD. bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at $52,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth about $81,000. Quest Partners LLC acquired a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $84,000. Finally, Straightline Group LLC bought a new stake in Amneal Pharmaceuticals during the 4th quarter worth about $92,000. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.